Radioimmunotherapy for malignant glioma

Malignant glioma is treated mainly by surgery with chemotherapy and external radiotherapy as adjuvant remedies. Survival time can be prolonged if appropriate radioimmunotherapy is employed as another concurrent alternative. Per-clinical, clinical phase I and II studies of ¹³¹I and ⁹⁰Y labeled anti-tenascin monoclonal antibodies in the treatment of malignant glioma have resulted in satisfactory therapeutic efficacy.